The American Cancer Society says more people will be diagnosed with cancer this year than ever before. Conventional treatments like surgery, chemotherapy, and radiation are helping to prevent deaths, but can more be done? Emerging research focused on repurposed drugs is proving the answer is YES.

The FLCCC Alliance is proud to announce it has partnered with renowned breast cancer physician and researcher Kathleen Ruddy, MD, to conduct an observational study in collaboration with four U.S. clinics to track patient responses to various adjunct cancer therapies using repurposed drugs. The aim is to determine changes in the five-year survival rate of several types of cancer including breast, prostate, lung, and colorectal.

FLCCC observational cancer study announcement

Study Details

FLCCC Cancer Study Announcement

Dr. Marik announces the cancer study partnership with Dr. Ruddy at the Winter 2024 FLCCC Educational Conference.

The final study results will focus on changes in the five-year survival rate of certain cancers and include patients from four clinics nationwide that will collaborate and share de-identified patient information in a protected data collection tool where the data will be tracked and analyzed.

Although the study uses the five-year survival rate after diagnosis as an endpoint, periodic updates of preliminary results will be provided while the study progresses. The study IRB has been officially approved by WCG, which places it in full compliance with all federal guidelines.

The FLCCC Alliance published its Cancer Care Monograph in June 2023. In the FLCCC research partnership with Dr. Ruddy, we hope to build on the already promising results she has documented. It is our mission to bring safe, affordable, and effective cancer treatments to the patients who so desperately need them.

How It Will Work

  • Participating clinics collaborate to share de-identified patient information.

  • Data is tracked and analyzed in a protected data collection tool.

  • FLCCC partners with four clinics across the United States for the study.

  • Each clinic ensures treatment aligns with patients’ wishes and doesn’t conflict with other treatments.

  • Interested patients can contact the participating clinics through provided contact links below.

Please Note: While there is no cost to enroll in the study, each patient will be responsible for the medical advice and treatment therapies provided by the participating clinics. Costs vary, since each clinic sets its own pricing – some focus on complementary care and work with the patients’ existing oncologists, while others provide end-to-end cancer care including a combination of traditional cancer treatments as well as complementary care using repurposed drugs. Clinic-based therapies are typically more expensive than telemedicine and costs will vary based on each patient’s medical history.

Study Leaders

Dr. Ruddy and Dr. Marik will act as lead investigators with Dr. Pierre Kory acting as contributing author.

Kathleen Ruddy, MD

Founder, Health and Healing
Lead Investigator, FLCCC Cancer Study

Paul E. Marik MD, FCCM, FCCP

Chief Scientific Officer, FLCCC
Lead Investigator, FLCCC Cancer Study

Pierre Kory, MD, MPA

Chief Medical Officer, FLCCC
Contributing Author, FLCCC Cancer Study

Participating Providers

Please inquire individually with participating providers that meet your state qualifications.